Skip to main content
. 2019 Apr 21;25(15):1840–1853. doi: 10.3748/wjg.v25.i15.1840

Table 1.

Correlations of Beclin1, LC3, and 4E-BP1 expression with clinicopathological characteristics in 68 advanced colorectal cancer patients n (%)

Variable n = 68 Beclin1 expression
LC3 expression
4E-BP1 expression
Low High P-value Low High P-value Low High P-value
Sex 0.061 0.372 0.571
Male 44 (64.7) 13 24 12 25 8 28
Female 24 (35.3) 2 17 4 15 3 16
Age (yr) 0.119 0.167 0.865
< 65 55 (80.9) 10 35 11 34 9 35
≥ 65 13 (19.1) 5 6 5 6 2 9
Family history of cancer 0.593 0.151 0.382
Yes 13 (19.1) 2 8 1 9 1 9
No 55 (80.9) 13 33 15 31 10 35
Location1 0.862 1.000 0.634
Left 50 (73.5) 11 31 12 30 2 33
Right 18 (26.5) 4 10 4 10 9 11
Pathological grade 0.349 0.349 8 0.897
1 + 2 44 (64.7) 8 30 8 30 8 29
3 18 (26.4) 5 10 5 10 3 12
NA 6 (8.9)
T stage 0.618 0.618 0.911
T1 + T2 + T3 41 (60.3) 9 24 9 24 6 26
T4 22 (32.4) 4 15 4 15 4 16
NA 5 (7.3)
N stage 0.058 0.058 0.654
No 22 (32.4) 6 9 6 9 4 12
N1 + N2 36 (52.9) 5 28 5 28 6 25
NA 10 (14.7)
Synchronous/metachronous metastasis 0.020 0.058 0.162
Synchronous metastasis 24 (35.3) 1 18 2 17 5 12
Metachronous metastasis 43 (63.2) 13 23 13 23 5 32
NA 1 (1.5)
KRAS 0.044 0.044 0.651
Wild type 45 (66.2) 13 24 13 24 7 30
Mutant type 10 (14.7) 0 9 0 9 2 6
NA 13 (19.1)

Location: The primary tumor location was classified as right-sided or left-sided according to the splenic flexure. CRC: Colorectal cancer; LC3: Microtubule-associated protein 1A/B-light chain 3; NA: Not applicable; 4E-BP1: 4E-binding protein 1.